Viking Therapeutics Files DEF 14A with SEC

TL;DR

<b>Viking Therapeutics filed its DEF 14A with the SEC on April 5, 2024, detailing executive compensation and equity award information.</b>

AI Summary

Viking Therapeutics, Inc. (VKTX) filed a Proxy Statement (DEF 14A) with the SEC on April 5, 2024. Viking Therapeutics, Inc. filed a DEF 14A form with the SEC on April 5, 2024. The filing is related to the fiscal year ending December 31, 2023. The company's principal business address is 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121. The filing includes detailed information on executive compensation, specifically equity awards. Key dates and events related to equity awards for 2021, 2022, and 2023 are referenced.

Why It Matters

For investors and stakeholders tracking Viking Therapeutics, Inc., this filing contains several important signals. This DEF 14A filing provides crucial transparency into Viking Therapeutics' executive compensation structure, particularly concerning equity awards, which can influence investor perception of management alignment and future dilution. The detailed breakdown of equity award values and changes over multiple years (2021-2023) allows investors to assess compensation trends and potential impacts on shareholder value.

Risk Assessment

Risk Level: low — Viking Therapeutics, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, providing standard disclosure on executive compensation and corporate governance, with no immediate material events indicated.

Analyst Insight

Investors should review the detailed executive compensation tables and equity award disclosures to understand potential dilution and management incentives.

Key Numbers

• 2024-04-05 — Filing Date (DEF 14A filing date)
• 2024-05-21 — Period of Report (Conformed period of report)
• 1231 — Fiscal Year End (Company fiscal year end)

Key Players & Entities

• Viking Therapeutics, Inc. (company) — Filer
• 0000950170-24-042251 (other) — Accession Number
• 2024-04-05 (date) — Filing Date
• 2024-05-21 (date) — Period of Report
• 001-37355 (other) — SEC File Number
• 9920 Pacific Heights Blvd, Suite 350, San Diego, CA 92121 (address) — Business Address
• 1934 Act (regulation) — SEC Act

FAQ

Industry Context

Viking Therapeutics operates in the pharmaceutical preparations industry, focusing on the development of novel therapies.

Regulatory Implications

The DEF 14A filing is a requirement under the Securities Exchange Act of 1934, mandating public companies to provide detailed information to shareholders regarding corporate actions and executive compensation.

What Investors Should Do

1. Review the executive compensation details, particularly equity awards and their valuation changes.
2. Analyze the filing for any changes in corporate governance practices.
3. Monitor future filings for updates on the company's strategic direction and financial performance.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure. Specific comparative data from a previous filing is not directly available in this extract.

Filing Documents

• vktx-20240405.htm (DEF 14A) — 1330KB
• img254162781_0.jpg (GRAPHIC) — 93KB
• img254162781_1.jpg (GRAPHIC) — 88KB
• img254162781_2.jpg (GRAPHIC) — 150KB
• img254162781_3.jpg (GRAPHIC) — 200KB
• 0000950170-24-042251.txt (&nbsp;) — 3292KB
• vktx-20240405.xsd (EX-101.SCH) — 35KB
• vktx-20240405_htm.xml (XML) — 146KB

From the Filing

DEF 14A U NITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ( Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 VIKING THERAPEUTICS, INC . (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. VIKING THERAPEUTICS, INC. 9920 Pacific Heights Blvd Suite 350, San Diego, CA 92121 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS Tuesday, May 21, 2024 8:00 a.m. Pacific Time https://web.lumiconnect.com/255403211 (password: viking2024) Dear Stockholder: You are cordially invited to attend the Annual Meeting of Stockholders (the " Annual Meeting ") of Viking Therapeutics, Inc., a Delaware corporation (the " Company "), or any adjournment or postponement thereof. The Annual Meeting will be held virtually, via live webcast at https://web.lumiconnect.com/255403211 (password: viking2024), on Tuesday, May 21, 2024, at 8:00 a.m. Pacific Time for the following purposes: 1. To elect the following nominees as Class III directors to serve until our 2027 Annual Meeting of Stockholders: Brian Lian, Ph.D. and Lawson Macartney, DVM, Ph.D.; 2. To ratify the selection of Marcum LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2024; 3. To approve, on an advisory basis, the compensation of our named executive officers; 4. To approve the Viking Therapeutics, Inc. 2024 Equity Incentive Plan; 5. To approve the Viking Therapeutics, Inc. 2024 Employee Stock Purchase Plan; and 6. To conduct any other business properly brought before the Annual Meeting and any adjournment or postponement thereof. These items of business are more fully described in the proxy statement accompanying this Notice of Internet Availability of Proxy Materials (the " Notice "). The record date for the Annual Meeting is March 28, 2024 (the " Record Date "). Only stockholders of record at the close of business on the Record Date may vote at the Annual Meeting or any adjournment or postponement thereof. This Notice is being mailed to all stockholders of record entitled to vote at the Annual Meeting on or about April 5, 2024. Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be held virtually, via live webcast at: https://web.lumiconnect.com/255403211 (password: viking2024), on Tuesday, May 21, 2024, at 8:00 a.m. Pacific Time. The accompanying proxy statement and annual report to stockholders are available at http://astproxyportal.com/ast/20061/. By Order of the Board of Directors /s/ Lawson Macartney, DVM, Ph.D. Lawson Macartney, DVM, Ph.D. Chairperson of the Board San Diego, California April 5, 2024 You are cordially invited to attend the Annual Meeting virtually. Whether or not you expect to attend the Annual Meeting, please complete, date, sign and return the enclosed proxy or submit your proxy through the internet or by telephone as promptly as possible in order to ensure your representation at the Annual Meeting. If you have requested physical materials to be mailed to you, then a return envelope (which is postage prepaid if mailed in the United States) is enclosed for your convenience if you choose to submit your proxy by mail. Even if you have voted by proxy, you may still vote electronically if you attend the Annual Meeting virtually. Please note, however, that if your shares are held of record by a broker, bank or other agent and you wish to vote electronically at the Annual Meeting, you must obtain a proxy issued in your name from that record holder . VIKING THERAPEUTICS, INC. 9920 Pacific Heights Blvd Suite 350, San Diego, CA 92121 PROXY STATEMENT FOR THE 2024 Annual Meeting OF STOCKHOLDERS TO BE HELD ON TUESDAY, MAY 21, 2024 QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING Why am I receiving these materials? We have sent you these proxy materials because the Board of Directors (our " Board ") of Viking Therapeutics, Inc. (sometimes referred to as " we ", " us ", " Viking " or the " Company ") is soliciting your proxy to vote at the 2024 Annual Meeting of Stockholders, or any adjournment or postponement thereof (the " Annual Meeting "). You are invited to attend the Annual Meeting virtually and we request that you vote on the proposals described in this proxy statement. Why did I receive a notice regarding the availabili

View Full Filing

View this DEF 14A filing on SEC EDGAR